- Prothena (NASDAQ:PRTA) presents new data at the AAIC 2021 from two of its Alzheimer’s disease (AD) programs.
- The presentations highlight new data for PRX012, the next-generation anti-amyloid beta (Aβ) antibody being developed for subcutaneous administration for patients with AD, as well as data on dual Aβ-tau vaccine program being developed for the prevention and treatment of AD.
- These two programs and Prothena’s anti-tau antibody partnered with Bristol Myers Squibb, PRX005, are part of Prothena’s AD portfolio.
- Results demonstrated that PRX012 induced significant microglia-mediated clearance of both pyroglutamate-modified and -unmodified Aß plaque in brain tissue of late-stage AD patients.
- PRX012 was observed to bind with very high affinity/avidity to full-length Aβ.
- PRX012 also showed higher potency and greater biologic activity than aducanumab.
- PRX012 IND application is expected to be filed in Q1 2022.
- Preclinical data on Prothena’s dual Aβ-tau vaccine were also described in a poster. The findings demonstrate dual Aβ-tau vaccines simultaneously generate antibodies that neutralize and clear pathogenic Aβ and block pathogenic tau interaction.
- Additionally, cerebrospinal fluid concentrations of tau and Aβ antibodies were within the expected range and similar to typical ranges achieved following administration of monoclonal antibodies (0.1-0.2% CSF/plasma).
- #AAIC21